initial public offerings (IPOs) trading on American exchanges

Friday, December 7, 2018

Moderna (MRNA) began trading on the Nasdaq on 7 December 2018

Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company that is focused on drug discovery and drug development based on messenger RNA (mRNA). The company creates synthetic mRNA that can be injected into patients to help them create their own therapies.
The pharma is shaping its mRNA platform into prophylactic and cancer vaccines, as well as immuno-oncology, regenerative and systemic therapeutics.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Sector: Healthcare
Industry: Biotechnology
Headquarters: Cambridge, Massachusetts
Number of employees: ~700
Founded: 2010
Offer size: $604 million; 21.7 million shares 

No comments:

Post a Comment